At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 430 enrolled
Drug / intervention
Ibrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
In Brief
A Phase 3 clinical trial evaluating Ibrutinib, Gemcitabine, and 1 other intervention for Metastatic Pancreatic Adenocarcinoma. Completed, enrolled 430 participants across 86 sites in 8 countries.
Detailed Summary
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Adenocarcinoma
CountriesBelgium, France, Germany, Italy, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionOct 2018
Study CompletionApr 2019
TodayJul 2026
First PostedMay 7, 2015
Enrollment StartMay 1, 2015
Primary CompletionOct 1, 2018
Study CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.2 years ago
Interventions
Ibrutinibdrug
Gemcitabinedrug
Nab-paclitaxeldrug